Navigation Links
Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
Date:1/8/2012

rantee that our Lincoln, NE production facility will reopen at any particular time. Nor can there be any guarantee that actions described in this release will be the only regulatory actions required at the Lincoln, NE facility.  Neither can there be any guarantee that further quality issues will not arise at any additional Novartis Group manufacturing facilities.  Nor can there be any guarantee as to the potential financial impact on Novartis resulting from the shutdown of the Lincoln, NE production facility. In particular, management's expectations could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected manufacturing issues, including unexpected inabilities to satisfy regulators' requirements for the reopening of the Lincoln, NE production facility; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisNovartis Group provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, pr
'/>"/>

SOURCE Novartis Consumer Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
2. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
3. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
4. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
5. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
6. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
7. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
8. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
9. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
10. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
11. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... YORK, Oct. 17, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0487169/Novo-Nordisk-A/S-PharmaVitae-Profile.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... the historical and forecast performance for Novo ...
... Inc. (NASDAQ: ANDS ) today announced that it has ... (SIX: RO, ROG; OTCQX: RHHBY). Under the terms of the merger ... outstanding shares of common stock of Anadys at USD 3.70 per ... represents a 256% premium over the closing price of USD 1.04 ...
Cached Medicine Technology:Novo Nordisk A/S: PharmaVitae Profile 2Anadys Announces Agreement To Be Acquired By Roche 2Anadys Announces Agreement To Be Acquired By Roche 3Anadys Announces Agreement To Be Acquired By Roche 4
(Date:4/17/2014)... has found that India,s shocking rates of suicide are ... are clinging to tiny smallholdings less than one ... as cotton and coffee, that are highly susceptible to ... of previous case studies that point to a crisis ... ,liberalisation, of the nation,s economy during the 90s. Researchers ...
(Date:4/17/2014)... adrenaline after they suffer a cardiac arrest outside of ... long-term, according to new research conducted at St. Michael,s ... a cardiac arrest get adrenaline, which has been the ... Dr. Steve Lin, an emergency physician and trauma team ... treatment, long-term survival rates of patients who suffer a ...
(Date:4/17/2014)... that lost its status as the leading weapon against ... of life, with new research indicating it simply needs ... the use of the cheap anti-malarial drug chloroquine in ... lives of more than half a million people each ... malaria has developed resistance to chloroquine, but research carried ...
(Date:4/16/2014)... , STANFORD, Calif. Consider the marvel of the embryo. ... shape and function as they multiply to become the cells ... tissues of the body. , Now, in a feat of ... the complex genetic coding that allows embryonic cells to proliferate ...
(Date:4/16/2014)... 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today ... CDX-1401 in solid tumors, including long-term patient follow-up, have ... 6 Issue 232). The data demonstrate robust antibody and ... patients with very advanced cancers and suggest that CDX-1401 ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... ... new book “A must have...The Maroema Cook Book” by Mamta Reid of Tokyo’s MAROEMA Vegetarian ... (PRWEB) May 6, ... new inspiration with the release of “A must have...The Maroema Cook Book” by Mamta Reid. ...
... heart disease and stroke rates in China will rise ... aging population and other increased risk factors, without policies ... smoking, according to research from Columbia University Medical Center ... an American Heart Association journal. "China,s standard of ...
... events , WEDNESDAY, May 5 (HealthDay News) -- A ... significantly cuts down on hospital drug errors, researchers from ... "We had the opportunity to design and implement a ... the hospital gets the right medication at the right ...
... Researchers at the University of Toronto have discovered a ... number of genes to generate enormously complex organs such as ... in the journal Nature entitled "Deciphering the Splicing ... Benjamin Blencowe of the University of Toronto describes how a ...
... Nausea in pregnant women tends to fade after the ... it can be a sign of flu, researchers at UT ... women who sought medical care. "People don,t necessarily think ... vomiting, but our study showed that they are common with ...
... finds , WEDNESDAY, May 5 (HealthDay News) -- People who,ve ... face an increased risk for heart complications and death if ... study has found. , "We looked at the risks connected ... Nicholas L.M. Cruden, a former cardiology lecturer at the University ...
Cached Medicine News:Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 2Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 3Health News:China facing public health crisis with projected increase in cardiovascular disease by 2030 2Health News:China facing public health crisis with projected increase in cardiovascular disease by 2030 3Health News:Bar Codes Cut Down on Hospital Medication Errors 2Health News:Bar Codes Cut Down on Hospital Medication Errors 3Health News:U of T researchers crack 'splicing code,' solve a mystery underlying biological complexity 2Health News:Nausea and speeding heart can be signs of flu in pregnant women 2Health News:Risks Rise for Other Surgeries After Stent Implants 2
... Acid is a non-irritating rapid exfoliator. Lactic Acid ... to peel and exfoliating agents in skin care ... other exfoliators for a long period and want ... occurring human metabolite, and combined with the chemical ...
... is available in two innovative formulations: Level ... active). The Level I (40% active) formulation ... extract, which DCL scientists have identified and ... and calm the skin while the beneficial ...
... CosmoDerm and CosmoPlast are dermal fillers ... acne scars and other soft tissue contour ... of the lip border. The collagen in ... dermal tissue that is grown under controlled ...
... is a gel of ... species of bacteria, chemically ... suspended in phosphate,buffered saline ... and concentration of 20 ...
Medicine Products: